Home›Stock Screener›Nephrocare Health Services

Nephrocare Health Services Share Price Today | Stock Price & Nephrocare Health Services Share Screener

NEPHROPLUS Healthcare Service Provider
Live Share Price NSE
₹637.65
▼ -11.30 (-1.74%)
2026-10-05 00:00:00
Live Share Price BSE
₹637.20
▼ -9.85 (-1.52%)
2026-10-05 00:00:00

As of October 5, 2026, the live Nephrocare Health Services share price (NSE: NEPHROPLUS) is ₹637.65 on NSE and ₹637.20 on BSE, down 1.74% from the previous close, with shares trading between ₹635.00 and ₹658.00 in today's trading session, and a 52-week range of ₹449.15–₹765.35. Check Nephrocare Health Services 52-week for the annual price range and momentum. Use the Nephrocare Health Services stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Nephrocare Health Services opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹289 and net income of ₹32, with EBITDA of ₹68, an operating margin of 21.0% and a profit margin of 11.1%.

Nephrocare Health Services Market Cap ₹6,657.01 Cr.
NEPHROPLUS P/E Ratio (TTM) 78.39
Nephrocare Health Services P/B Ratio 5.97
EPS (TTM) ₹8.48
Dividend Yield -
Debt to Equity 0.20
NEPHROPLUS 52 Week High ₹765.35
Nephrocare Health Services 52 Week Low ₹449.15
Operating Margin 21.00%
Profit Margin 11.07%
NEPHROPLUS Revenue (TTM) ₹289.00
EBITDA ₹68.00
Net Income ₹32.00
Total Assets ₹1,471.00
Total Equity ₹1,117.00

Nephrocare Health Services Share Price Chart

Track the current stock price of Nephrocare Health Services with an interactive chart. Analyse NEPHROPLUS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Nephrocare Health Services stock quote in one place.

The quote of ₹637.65 sits between the 52-week low of ₹449.15 and the 52-week high of ₹765.35, and the latest session moved -1.74% from the previous close.

Nephrocare Health Services Company Profile - Fundamental Screener

Screen Nephrocare Health Services company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NEPHROPLUS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare Services sector and the Healthcare Service Provider industry, and it trades under ISIN INE428V01029.

Company Details

Classification

Sector Healthcare Services
Industry Healthcare Service Provider
Sub-Sector Healthcare Service Provider
Segment E

Identifiers and Leadership

ISIN INE428V01029

Nephrocare Health Services Balance Sheet Screener

Screen NEPHROPLUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,471, up from ₹997 in 2025.

Latest statistics put total assets at ₹1,471 and shareholder funds at ₹1,117, with a leverage ratio of 0.20.

Item 2026 2025 2024 2023 2022 2021

Assets

Total Assets 1,471 997 806 666 571 428
Current Assets 839 545 390 324 285 178
Fixed Assets 517 396 356 239 205 192

Liabilities

Total Liabilities 0 0 0 0 0 0
Current Liabilities 55 129 150 103 81 75
Non-Current Liabilities 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,117 584 414 389 396 259
Share Capital 20 2 2 5 5 4
Reserves & Surplus 1,096 579 409 384 387 245

Nephrocare Health Services Income Statement Screener - Profit & Revenue Analysis

Screen Nephrocare Health Services income statement and profit fundamentals. Analyze NEPHROPLUS quarterly results. Nephrocare Health Services reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹289 and net profit was ₹32, equal to earnings per unit of ₹3.19, at an operating margin of 21%.

In that period expenses were ₹221, interest cost ₹2 and tax ₹9. The next period listed, 2026-Mar, shows revenue of ₹277 and net profit of ₹30.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Revenue and Expenses

Revenue 289 277 263 250 234 223 203
Expenses 221 215 199 182 180 168 153

Operating Costs and Margins

EBITDA 68 62 64 68 54 55 50
Operating Profit % 21.00% 19.00% 23.00% 26.00% 21.00% 23.00% 22.00%
Depreciation 25 26 22 23 20 19 18
Interest 2 3 6 45 6 6 5

Profit and Earnings

Profit Before Tax 41 33 36 -1 29 30 26
Tax 9 3 4 9 5 5 6
Net Profit 32 30 32 -10 24 25 20
EPS 3.19 3.03 3.43 -1.12 2.82 3.05 2.47

Nephrocare Health Services Cash Flow Screener - Liquidity Fundamentals

Screen NEPHROPLUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹233, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹392 and financing activities provided ₹157.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March

Cash from Operations and Investing

Operating Activities 233 135 72 11 14 32
Investing Activities -392 -125 -52 -76 -130 -62

Financing and Net Cash

Financing Activities 157 54 27 60 121 36
Net Cash Flow -2 65 47 -5 6 5

Nephrocare Health Services Shareholding Pattern Screener

See Nephrocare Health Services shareholding pattern with promoter, FII, and DII holdings. Check Nephrocare Health Services promoter holding and ownership changes for NEPHROPLUS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Jun, promoters held 63.85%, foreign institutions 8.78%, domestic institutions 9.05% and the public 5.70%, spread across 44,091 shareholders.

The shareholder count was 44,091 in 2026-Jun, compared with 43,409 in 2026-Mar.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Jul

Promoter Holding

Promoter Holding 63.85% 63.85% 63.85% 79.05%

Institutional Investors

FII Holding 8.78% 9.94% 9.30% 0.00%
DII Holding 9.05% 8.65% 8.10% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00%
Public Holding 5.70% 5.08% 5.92% 0.00%
Other Holding 12.62% 12.48% 12.82% 20.94%
Shareholder Count 44,091 43,409 36 65

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Nephrocare Health Services. Nephrocare Health Services dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Nephrocare Health Services.

Nephrocare Health Services Stock Index Membership - Nifty & Sensex

See which indices include Nephrocare Health Services stock. Check NEPHROPLUS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Nephrocare Health Services is not part of any tracked indices.
Only major market indices are tracked in our system.

Nephrocare Health Services Market Events Screener - Corporate Actions

Get Nephrocare Health Services corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Nephrocare Health Services stock events that may affect NEPHROPLUS share price, along with derivatives, futures and options activity and sector gainers.

4 corporate actions are listed, the most recent entry being Annual General Meeting dated August 12, 2026, with a record date of August 12, 2026.

It is followed by Quarterly Result Announcement dated August 11, 2026 and Quarterly Result Announcement dated May 19, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-12 2026-08-12 Annual General Meeting NA 12.01%
2026-08-11 2026-08-11 Quarterly Result Announcement NA 2.67%
2026-05-19 2026-05-19 Quarterly Result Announcement NA 21.32%
2026-02-10 2026-02-10 Quarterly Result Announcement NA 2.85%

Nephrocare Health Services Competitors Screener - Peer Stocks Comparison

Screen NEPHROPLUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Dr. Lal Path Labs 32,185 60.10 2,864 12.11% 510 58.55
Vijaya Diagnostic Centre 14,970 81.17 835 19.34% 173 47.24
Metropolis Healthcare 11,284 57.53 1,671 24.15% 191 40.73
Thyrocare Technologies 8,647 49.47 846 20.48% 163 40.51
Nephrocare Health Services 6,657 78.39 1,023 32.93% 77 35.51
Suraksha Diagnostic 1,841 52.79 314 22.55% 31 65.77
Krsnaa Diagnostics 1,804 18.47 816 9.90% 101 50.95
3B BlackBio DX 1,482 24.79 142 27.17% 61 68.55
One Global Service Provider 1,031 14.13 499 237.48% 70 45.89
Health X Platform 913 -34.91 1,378 17.65% -1 37.93

Nephrocare Health Services Company Announcements - News & Reports Screener

Screen NEPHROPLUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 5, 2026.

The next most recent announcements are dated October 2, 2026 and September 29, 2026.

Date Update Actions
2026-10-05 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-10-02 Closure of Trading Window -
2026-09-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-18 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-18 Announcement under Regulation 30 (LODR)-Restructuring -
2026-09-14 Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements -
2026-09-03 Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026. -
2026-09-01 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-31 Disclosure Under Regulation 30 Of SEBI Listing Regulations -
2026-08-19 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-17 Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements -
2026-08-13 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-13 Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements -
2026-08-12 Announcement under Regulation 30 (LODR)-Updates on Acquisition -
2026-08-12 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-12 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-11 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-08-11 Board Meeting Outcome for Outcome Of Board Meeting Held On August 11 2026. -
2026-08-11 Announcement under Regulation 30 (LODR)-Press Release / Media Release -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹637.65, within a 52-week range of ₹449.15 to ₹765.35. The P/E ratio is 78.39 and the P/B ratio is 5.97, with earnings per unit of ₹8.48. Market capitalisation stands at ₹6,657.01 Cr. The company operates in the Healthcare Services sector, in the Healthcare Service Provider industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 6 balance sheet periods, 7 income statement periods, 6 cash flow years and 4 shareholding periods. Information is provided for research and is not investment advice.